Orange Book product · Brand (NDA)
GIAPREZA
ANGIOTENSIN II ACETATE
At a glance
Dec 23, 2021
Approved
Brand (NDA)
Application
Not listed
TE code
15
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Dec 23, 2021
4 yr 7 mo ago
Today
Patent 10335451 expires
Listed method-of-use patent (U-2581) expiration.
Dec 16, 2029
in 3 yr 7 mo
Patent 10500247 expires
Listed method-of-use patent (U-2681) expiration.
Dec 16, 2029
in 3 yr 7 mo
Patent 10500247 expires
Listed method-of-use patent (U-2680) expiration.
Dec 16, 2029
in 3 yr 7 mo
Patent 10548943 expires
Listed method-of-use patent (U-2740) expiration.
Dec 16, 2029
in 3 yr 7 mo
Patent 10548943 expires
Listed method-of-use patent (U-2739) expiration.
Dec 16, 2029
in 3 yr 7 mo
Patent 9867863 expires
Listed method-of-use patent (U-2231) expiration.
Dec 16, 2029
in 3 yr 7 mo
Patent 9572856 expires
Listed method-of-use patent (U-2221) expiration.
Jul 18, 2031
in 5 yr 2 mo
Patent 10028995 expires
Listed method-of-use patent (U-2338) expiration.
Dec 18, 2034
in 8 yr 7 mo
Patent 10493124 expires
Listed method-of-use patent (U-2679) expiration.
Dec 18, 2034
in 8 yr 7 mo
Patent 11096983 expires
Listed method-of-use patent (U-3212) expiration.
Dec 18, 2034
in 8 yr 7 mo
Patent 11096983 expires
Listed method-of-use patent (U-3211) expiration.
Dec 18, 2034
in 8 yr 7 mo
Patent 11559559 expires
Listed method-of-use patent (U-3514) expiration.
Dec 18, 2034
in 8 yr 7 mo
Patent 9220745 expires
Listed method-of-use patent (U-2217) expiration.
Dec 18, 2034
in 8 yr 7 mo
Patent 9220745 expires
Listed method-of-use patent (U-2218) expiration.
Dec 18, 2034
in 8 yr 7 mo
Patent 11219662 expires
Listed method-of-use patent (U-3262) expiration.
Jan 06, 2037
in 10 yr 8 mo
Pharmaceutical detail
Active ingredient
ANGIOTENSIN II ACETATE
Strength
EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML)
Dosage form
SOLUTION
Route
INTRAVENOUS
TE code
Not listed
Application
NDA 209360
Product number
003
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (15)
| Patent | Expires | In | Type |
|---|---|---|---|
| 10335451 | Dec 16, 2029 | in 3 yr 7 mo | U-2581 |
| 10500247 | Dec 16, 2029 | in 3 yr 7 mo | U-2681 |
| 10500247 | Dec 16, 2029 | in 3 yr 7 mo | U-2680 |
| 10548943 | Dec 16, 2029 | in 3 yr 7 mo | U-2740 |
| 10548943 | Dec 16, 2029 | in 3 yr 7 mo | U-2739 |
| 9867863 | Dec 16, 2029 | in 3 yr 7 mo | U-2231 |
| 9572856 | Jul 18, 2031 | in 5 yr 2 mo | U-2221 |
| 10028995 | Dec 18, 2034 | in 8 yr 7 mo | U-2338 |
| 10493124 | Dec 18, 2034 | in 8 yr 7 mo | U-2679 |
| 11096983 | Dec 18, 2034 | in 8 yr 7 mo | U-3212 |
| 11096983 | Dec 18, 2034 | in 8 yr 7 mo | U-3211 |
| 11559559 | Dec 18, 2034 | in 8 yr 7 mo | U-3514 |
| 9220745 | Dec 18, 2034 | in 8 yr 7 mo | U-2217 |
| 9220745 | Dec 18, 2034 | in 8 yr 7 mo | U-2218 |
| 11219662 | Jan 06, 2037 | in 10 yr 8 mo | U-3262 |
